- Home
- NAUT vs ZNTL Comparison
NAUT vs ZNTL Comparison
Compare NAUT & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAUT
- ZNTL
- Stock Information
- Founded
- NAUT 2016
- ZNTL 2014
- Country
- NAUT United States
- ZNTL United States
- Employees
- NAUT N/A
- ZNTL N/A
- Industry
- NAUT Biotechnology: Laboratory Analytical Instruments
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- NAUT Industrials
- ZNTL Health Care
- Exchange
- NAUT Nasdaq
- ZNTL Nasdaq
- Market Cap
- NAUT 86.4M
- ZNTL 102.2M
- IPO Year
- NAUT N/A
- ZNTL 2020
- Fundamental
- Price
- NAUT $0.77
- ZNTL $1.36
- Analyst Decision
- NAUT Hold
- ZNTL Buy
- Analyst Count
- NAUT 3
- ZNTL 9
- Target Price
- NAUT $3.58
- ZNTL $8.69
- AVG Volume (30 Days)
- NAUT 167.3K
- ZNTL 725.4K
- Earning Date
- NAUT 04-29-2025
- ZNTL 05-14-2025
- Dividend Yield
- NAUT N/A
- ZNTL N/A
- EPS Growth
- NAUT N/A
- ZNTL N/A
- EPS
- NAUT N/A
- ZNTL N/A
- Revenue
- NAUT N/A
- ZNTL $26,865,000.00
- Revenue This Year
- NAUT N/A
- ZNTL N/A
- Revenue Next Year
- NAUT N/A
- ZNTL N/A
- P/E Ratio
- NAUT N/A
- ZNTL N/A
- Revenue Growth
- NAUT N/A
- ZNTL N/A
- 52 Week Low
- NAUT $0.66
- ZNTL $1.01
- 52 Week High
- NAUT $3.09
- ZNTL $12.68
- Technical
- Relative Strength Index (RSI)
- NAUT 48.86
- ZNTL 55.35
- Support Level
- NAUT $0.71
- ZNTL $1.19
- Resistance Level
- NAUT $0.85
- ZNTL $1.27
- Average True Range (ATR)
- NAUT 0.07
- ZNTL 0.07
- MACD
- NAUT 0.00
- ZNTL 0.02
- Stochastic Oscillator
- NAUT 26.72
- ZNTL 85.11
About NAUT Nautilus Biotechnolgy Inc.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.